Rates of VTE in relation to potential risk factors
| . | No. of patients . | Events . | Person-years* . | AR . | Univariable Cox model . | Multivariable Cox model‡ . | |||
|---|---|---|---|---|---|---|---|---|---|
| Rate† . | 95% CI . | HR . | 95% CI . | HR . | 95% CI . | ||||
| Stage | |||||||||
| Local disease | 5 037 | 214 | 31.4 | 6.8 | 6.0-7.8 | Ref | Ref | ||
| Regional disease | 2 961 | 161 | 16.3 | 9.9 | 8.5-11.6 | 1.4 | 1.2-1.8 | 1.2 | 0.9-1.4 |
| Distant Metastases | 470 | 21 | 1.2 | 18.2 | 11.9-28.0 | 2.5 | 1.6-4.0 | 1.5 | 1.0-2.4 |
| Unknown | 4 734 | 215 | 23.8 | 9.0 | 7.9-10.3 | 1.3 | 1.1-1.6 | 1.2 | 0.9-1.4 |
| Grade | |||||||||
| Well differentiated | 1 681 | 71 | 11.1 | 6.4 | 5.1-8.1 | Ref | Ref | ||
| Moderately differentiated | 4 232 | 196 | 25.1 | 7.8 | 6.8-9.0 | 1.3 | 1.0-1.7 | 1.1 | 0.8-1.5 |
| Poorly differentiated | 3 024 | 166 | 16.1 | 10.3 | 8.9-12.0 | 1.2 | 0.9-1.6 | 1.1 | 0.8-1.4 |
| Unknown | 4 265 | 178 | 20.3 | 8.7 | 7.6-10.1 | 1.6 | 1.2-2.1 | 1.3 | 1.0-1.7 |
| Surgery | |||||||||
| No surgery | 3 093 | 104 | 11.5 | 9.0 | 7.4-10.9 | Ref | Ref | ||
| Before surgery | 13 | 1.5 | 8.7 | 5.1-15.0 | 0.9 | 0.5-1.6 | 0.7 | 0.4-1.2 | |
| During surgery hospitalization | 3 | 0.2 | 17.9 | 5.8-55.5 | 1.7 | 0.6-5.5 | 1.5 | 0.5-4.9 | |
| First month after discharge | 26 | 1.1 | 23.5 | 16.0-34.5 | 2.4 | 1.6-3.8 | 2.2 | 1.4-3.4 | |
| Second month after discharge | 24 | 1.0 | 24.3 | 16.3-36.2 | 2.4 | 1.5-3.8 | 1.4 | 0.9-2.2 | |
| Third month after discharge | 12 | 1.0 | 12.6 | 7.2-22.2 | 1.2 | 0.7-2.2 | 0.6 | 0.3-1.1 | |
| Subsequent time | 429 | 56.3 | 7.6 | 6.9-8.4 | 0.9 | 0.7-1.1 | 1.0 | 0.8-1.3 | |
| Chemotherapy | |||||||||
| No chemotherapy | 10 429 | 422 | 57.1 | 7.4 | 6.7-8.1 | Ref | Ref | ||
| Before chemotherapy | 31 | 2.7 | 11.7 | 8.2-16.6 | 1.5 | 1.0-2.1 | 1.6 | 1.1-2.4 | |
| During chemotherapy | 1.3 | 59.6 | 47.7-74.5 | 7.7 | 6.0-9.8 | 10.8 | 8.2-14.4 | ||
| First month after completion | 15 | 0.3 | 51.6 | 31.1-85.5 | 6.5 | 3.9-10.9 | 8.4 | 4.9-14.2 | |
| Second month after completion | 8 | 0.2 | 33.1 | 16.6-66.3 | 4.0 | 2.0-8.1 | 4.5 | 2.2-9.3 | |
| Third month after completion | 3 | 0.2 | 13.5 | 4.4-41.9 | 1.8 | 0.6-5.5 | 2.0 | 0.6-6.3 | |
| Subsequent time | 55 | 10.8 | 5.1 | 3.9-6.7 | 0.7 | 0.5-0.9 | 1.1 | 0.8-1.5 | |
| Endocrine therapy | |||||||||
| No endocrine therapy | 2 323 | 87 | 9.8 | 8.9 | 7.2-11.0 | Ref | Ref | ||
| Before endocrine therapy | 54 | 3.0 | 17.8 | 13.7-23.3 | 1.9 | 1.3-2.6 | 1.2 | 0.8-1.7 | |
| First 3 months of endocrine therapy | 69 | 2.5 | 27.7 | 21.9-35.0 | 2.9 | 2.1-4.0 | 2.4 | 1.7-3.4 | |
| Subsequent time | 401 | 57.3 | 7.0 | 6.3-7.7 | 0.8 | 0.6-1.0 | 0.9 | 0.7-1.1 | |
| Body mass index (kg/m2) | |||||||||
| Underweight (<18.5) | 192 | 4 | 1.1 | 3.8 | 1.4-10.1 | 0.7 | 0.3-2.0 | 0.7 | 0.3-1.9 |
| Ideal (18.5-24.9) | 3 099 | 93 | 18.3 | 5.1 | 4.2-6.2 | Ref | Ref | ||
| Overweight (25.0-29.9) | 2 520 | 148 | 14.7 | 10.1 | 8.6-11.8 | 2.0 | 1.5-2.6 | 1.8 | 1.4-2.4 |
| Obese (30.0-39.9) | 1 119 | 73 | 6.4 | 11.4 | 9.1-14.3 | 2.2 | 1.6-3.0 | 2.1 | 1.6-2.9 |
| Morbidly obese (≥40.0) | 440 | 38 | 2.3 | 16.5 | 12.0-22.7 | 3.2 | 2.2-4.7 | 3.0 | 2.1-4.4 |
| Missing | 5 832 | 255 | 29.9 | 8.5 | 7.6-9.7 | 1.6 | 1.3-2.0 | 1.5 | 1.2-1.9 |
| Age (years) | |||||||||
| <40 | 715 | 21 | 4.1 | 5.1 | 3.4-7.9 | Ref | Ref | ||
| 40-49 | 2 030 | 63 | 12.7 | 5.0 | 3.9-6.3 | 1.0 | 0.6-1.7 | 1.1 | 0.7-1.8 |
| 50-59 | 3 262 | 108 | 20.7 | 5.2 | 4.3-6.3 | 1.1 | 0.7-1.7 | 1.3 | 0.8-2.1 |
| 60-69 | 2 973 | 179 | 17.7 | 10.1 | 8.7-11.7 | 2.1 | 1.3-3.3 | 2.9 | 1.8-4.6 |
| 70-79 | 2 407 | 158 | 11.9 | 13.3 | 11.4-15.5 | 2.7 | 1.7-4.2 | 4.2 | 2.6-6.7 |
| ≥80 | 1 815 | 82 | 5.5 | 14.9 | 12.0-18.4 | 2.9 | 1.8-4.7 | 5.0 | 3.0-8.2 |
| Charlson score | |||||||||
| 0 | 6 987 | 295 | 37.5 | 7.8 | 7.1-8.8 | Ref | Ref | ||
| 1-3 | 5 860 | 293 | 33.6 | 8.7 | 7.8-9.8 | 1.1 | 1.0-1.4 | 1.0 | 0.8-1.1 |
| ≥4 | 355 | 23 | 1.5 | 15.4 | 10.2-23.1 | 2.1 | 1.4-3.3 | 1.3 | 0.9-2.1 |
| . | No. of patients . | Events . | Person-years* . | AR . | Univariable Cox model . | Multivariable Cox model‡ . | |||
|---|---|---|---|---|---|---|---|---|---|
| Rate† . | 95% CI . | HR . | 95% CI . | HR . | 95% CI . | ||||
| Stage | |||||||||
| Local disease | 5 037 | 214 | 31.4 | 6.8 | 6.0-7.8 | Ref | Ref | ||
| Regional disease | 2 961 | 161 | 16.3 | 9.9 | 8.5-11.6 | 1.4 | 1.2-1.8 | 1.2 | 0.9-1.4 |
| Distant Metastases | 470 | 21 | 1.2 | 18.2 | 11.9-28.0 | 2.5 | 1.6-4.0 | 1.5 | 1.0-2.4 |
| Unknown | 4 734 | 215 | 23.8 | 9.0 | 7.9-10.3 | 1.3 | 1.1-1.6 | 1.2 | 0.9-1.4 |
| Grade | |||||||||
| Well differentiated | 1 681 | 71 | 11.1 | 6.4 | 5.1-8.1 | Ref | Ref | ||
| Moderately differentiated | 4 232 | 196 | 25.1 | 7.8 | 6.8-9.0 | 1.3 | 1.0-1.7 | 1.1 | 0.8-1.5 |
| Poorly differentiated | 3 024 | 166 | 16.1 | 10.3 | 8.9-12.0 | 1.2 | 0.9-1.6 | 1.1 | 0.8-1.4 |
| Unknown | 4 265 | 178 | 20.3 | 8.7 | 7.6-10.1 | 1.6 | 1.2-2.1 | 1.3 | 1.0-1.7 |
| Surgery | |||||||||
| No surgery | 3 093 | 104 | 11.5 | 9.0 | 7.4-10.9 | Ref | Ref | ||
| Before surgery | 13 | 1.5 | 8.7 | 5.1-15.0 | 0.9 | 0.5-1.6 | 0.7 | 0.4-1.2 | |
| During surgery hospitalization | 3 | 0.2 | 17.9 | 5.8-55.5 | 1.7 | 0.6-5.5 | 1.5 | 0.5-4.9 | |
| First month after discharge | 26 | 1.1 | 23.5 | 16.0-34.5 | 2.4 | 1.6-3.8 | 2.2 | 1.4-3.4 | |
| Second month after discharge | 24 | 1.0 | 24.3 | 16.3-36.2 | 2.4 | 1.5-3.8 | 1.4 | 0.9-2.2 | |
| Third month after discharge | 12 | 1.0 | 12.6 | 7.2-22.2 | 1.2 | 0.7-2.2 | 0.6 | 0.3-1.1 | |
| Subsequent time | 429 | 56.3 | 7.6 | 6.9-8.4 | 0.9 | 0.7-1.1 | 1.0 | 0.8-1.3 | |
| Chemotherapy | |||||||||
| No chemotherapy | 10 429 | 422 | 57.1 | 7.4 | 6.7-8.1 | Ref | Ref | ||
| Before chemotherapy | 31 | 2.7 | 11.7 | 8.2-16.6 | 1.5 | 1.0-2.1 | 1.6 | 1.1-2.4 | |
| During chemotherapy | 1.3 | 59.6 | 47.7-74.5 | 7.7 | 6.0-9.8 | 10.8 | 8.2-14.4 | ||
| First month after completion | 15 | 0.3 | 51.6 | 31.1-85.5 | 6.5 | 3.9-10.9 | 8.4 | 4.9-14.2 | |
| Second month after completion | 8 | 0.2 | 33.1 | 16.6-66.3 | 4.0 | 2.0-8.1 | 4.5 | 2.2-9.3 | |
| Third month after completion | 3 | 0.2 | 13.5 | 4.4-41.9 | 1.8 | 0.6-5.5 | 2.0 | 0.6-6.3 | |
| Subsequent time | 55 | 10.8 | 5.1 | 3.9-6.7 | 0.7 | 0.5-0.9 | 1.1 | 0.8-1.5 | |
| Endocrine therapy | |||||||||
| No endocrine therapy | 2 323 | 87 | 9.8 | 8.9 | 7.2-11.0 | Ref | Ref | ||
| Before endocrine therapy | 54 | 3.0 | 17.8 | 13.7-23.3 | 1.9 | 1.3-2.6 | 1.2 | 0.8-1.7 | |
| First 3 months of endocrine therapy | 69 | 2.5 | 27.7 | 21.9-35.0 | 2.9 | 2.1-4.0 | 2.4 | 1.7-3.4 | |
| Subsequent time | 401 | 57.3 | 7.0 | 6.3-7.7 | 0.8 | 0.6-1.0 | 0.9 | 0.7-1.1 | |
| Body mass index (kg/m2) | |||||||||
| Underweight (<18.5) | 192 | 4 | 1.1 | 3.8 | 1.4-10.1 | 0.7 | 0.3-2.0 | 0.7 | 0.3-1.9 |
| Ideal (18.5-24.9) | 3 099 | 93 | 18.3 | 5.1 | 4.2-6.2 | Ref | Ref | ||
| Overweight (25.0-29.9) | 2 520 | 148 | 14.7 | 10.1 | 8.6-11.8 | 2.0 | 1.5-2.6 | 1.8 | 1.4-2.4 |
| Obese (30.0-39.9) | 1 119 | 73 | 6.4 | 11.4 | 9.1-14.3 | 2.2 | 1.6-3.0 | 2.1 | 1.6-2.9 |
| Morbidly obese (≥40.0) | 440 | 38 | 2.3 | 16.5 | 12.0-22.7 | 3.2 | 2.2-4.7 | 3.0 | 2.1-4.4 |
| Missing | 5 832 | 255 | 29.9 | 8.5 | 7.6-9.7 | 1.6 | 1.3-2.0 | 1.5 | 1.2-1.9 |
| Age (years) | |||||||||
| <40 | 715 | 21 | 4.1 | 5.1 | 3.4-7.9 | Ref | Ref | ||
| 40-49 | 2 030 | 63 | 12.7 | 5.0 | 3.9-6.3 | 1.0 | 0.6-1.7 | 1.1 | 0.7-1.8 |
| 50-59 | 3 262 | 108 | 20.7 | 5.2 | 4.3-6.3 | 1.1 | 0.7-1.7 | 1.3 | 0.8-2.1 |
| 60-69 | 2 973 | 179 | 17.7 | 10.1 | 8.7-11.7 | 2.1 | 1.3-3.3 | 2.9 | 1.8-4.6 |
| 70-79 | 2 407 | 158 | 11.9 | 13.3 | 11.4-15.5 | 2.7 | 1.7-4.2 | 4.2 | 2.6-6.7 |
| ≥80 | 1 815 | 82 | 5.5 | 14.9 | 12.0-18.4 | 2.9 | 1.8-4.7 | 5.0 | 3.0-8.2 |
| Charlson score | |||||||||
| 0 | 6 987 | 295 | 37.5 | 7.8 | 7.1-8.8 | Ref | Ref | ||
| 1-3 | 5 860 | 293 | 33.6 | 8.7 | 7.8-9.8 | 1.1 | 1.0-1.4 | 1.0 | 0.8-1.1 |
| ≥4 | 355 | 23 | 1.5 | 15.4 | 10.2-23.1 | 2.1 | 1.4-3.3 | 1.3 | 0.9-2.1 |
Subsequent time refers to the time and rate after the procedure until the completion of follow-up.
Ref, reference.
Divided by 1000.
Per 1000 person-years.
HRs adjusted for all other variables in the table. All variables were fitted by using the categorization displayed in the table (ie, age group as a 6-level nonordered categorical variable).